PR

Press release

Promotion

Notice

MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

Admin │ 2022-12-05

HIT

518

https://www.globenewswire.com/news-release/2022/12/05/2567044/0/en/MaxCyte-Signs-Strategic-Platform-License-with-Curamys-to-Enable-Cell-Gene-Therapies-for-the-Treatment-of-Rare-Intractable-Diseases.html

https://markets.businessinsider.com/news/stocks/maxcyte-curamys-in-strategic-platform-license-deal-1031952309

https://www.lse.co.uk/news/maxcyte-inks-deal-with-south-koreas-curamys-9fsmp30t3qepw2e.html

Prev	"We will overcome intractable Lou Gehrig's disease & Duchenne disease."
Next	No next post.